Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
August 23, 2014, 02:12:05 PM

Login with username, password and session length


Members
  • Total Members: 23305
  • Latest: anji
Stats
  • Total Posts: 635820
  • Total Topics: 48239
  • Online Today: 314
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 5
Guests: 170
Total: 175

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: VIRxSYS announcement at AIDS Vaccine Conference  (Read 1720 times)

0 Members and 1 Guest are viewing this topic.

Offline loneranger

  • Member
  • Posts: 16
VIRxSYS announcement at AIDS Vaccine Conference
« on: October 01, 2010, 10:35:41 AM »
Hi all

Came across this on the web this afternoon. Interesting news!

http://www.euroinvestor.co.uk/news/story.aspx?id=11320744&bw=20100930006693


VIRxSYS Corporation Demonstrates “Functional Cure” and Survival Benefit for the simian model of HIV in Preclinical Vaccine Study

VIRxSYS Corporation, a privately held company developing vaccines

and RNA therapies for serious human diseases,today presented

results from a study of VRX1116, a simian analog for an investigational,

lentiviral-based vaccine for HIV VRX1273, at the AIDS Vaccine 2010

conference in Atlanta, GA. In this prophylactic non human primate study,

two out of five monkeys immunized with the vaccine were able to

“functionally cure,” or fully control and suppress viral replication

over time after challenge with a highly pathogenic simian

immunodeficiency virus (SIV), and have shown stable or increased CD4

counts compared to pre-challenge baselines Additionally, the death of

several monkeys in the control, unvaccinated group showed that

VRX1116-based vaccination was capable of conferring a survival benefit

following SIV infection. The vaccine was safely and repeatedly

administered and proved to be highly immunogenic with sustained immune

responses. Virological and immunological benefits, including control of

viral load and preservation of the CD4 compartment, were sustained for

as long as one year post-challenge.

"We and HIV key opinion leaders are very optimistic about these

long-term results showing viral suppression, protection of the immune

system and survival in this prophylactic study.” said Gary J. McGarrity,

PhD, Executive Vice President of Scientific and Clinical Affairs at

VIRxSYS Corporation. “In addition, the full control of SIV replication

following infection of two of our monkeys is a significant milestone in

our research to develop effective therapeutic and prophylactic vaccines

for HIV.”

VIRxSYS’ investigational VRX1273 vaccine is part of the company’s work

to create a therapeutic HIV vaccine to potentially lower HIV

transmission rates and improve the lives of millions of individuals

infected with HIV worldwide who – if they have access at all – must rely

on expensive drugs associated with serious side effects to help control

their infection. VIRxSYS is the only biotechnology company using

lentiviral vectors to develop a therapeutic HIV vaccine.

AIDS Vaccine 2010 is being held September 28 - October 1, 2010 at the

Omni Hotel in Atlanta, Georgia. The VRX1116 data was presented as

“Highly immunogenic lentiviral vaccine provides control of viral load,

preservation of the CD4 compartment, and survival advantage post-SIV

challenge.”

About VIRxSYS

Founded in 1998, VIRxSYS is a private biotechnology company

that develops therapies for the treatment of serious

human diseases utilizing its proprietary lentiviral vector and RNA

reprogramming platforms. The Company exclusively licensed its patented

lentiviral technology from The Johns Hopkins University and acquired its

SMaRT™ RNA reprogramming technology from Intronn Inc. More information

regarding VIRxSYS can be found at www.virxsys.com.

About VIRxSYS’ HIV Vaccine Program

VIRxSYS’ lentiviral vector vaccine program is testing investigational

HIV vaccine candidates for therapeutic and/or prophylactic use. The

company’s vaccine candidates against HIV are currently being evaluated

in preclinical studies in non-human primates.

Corinth Group Communications

Russell LaMontagne, 917-744-7957


Offline tednlou2

  • Member
  • Posts: 4,819
Re: VIRxSYS announcement at AIDS Vaccine Conference
« Reply #1 on: October 06, 2010, 11:18:25 PM »
I just saw this story on the new side-bar, widget thingy.  If this has been done in monkeys, is it far-fetched that this could be achieved in humans?  With the advances in science, should we know within the decade whether we can achieve a cure or functional cure, or whether it just isn't possible?

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.